Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis

Nature Clinical Practice Oncology

Volumn 3, Issue 1, 2006, Pages 41-49

  Blair, Julie M ^a   Zhou, Hong ^a   Seibel, Markus J ^b   Dunstan, Colin R ^a  

^a ANZAC RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMGEN; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; FC RECEPTOR; INTERLEUKIN 8; LECTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RECOMBINANT INTERLEUKIN 8; RECOMBINANT PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DESTRUCTION; BONE DEVELOPMENT; BONE METASTASIS; BONE REMODELING; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MUSCULOSKELETAL SYSTEM; NF-KAPPA B; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 30944436527     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0381     Document Type: Review

References (79)

1. Mundy GR (2002) Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593
2. Roudier MP et al. (2004) Histological, immunophenotypic and histomorphometric characterisation of prostate cancer bone metastasis. In The Biology of Skeletal Metastases, 311-339 (Eds Keller ET and Chung LWK) Boston: Kluwer Academic Publishers
3. Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bowie disease. Nat Clin Pract Oncol 2: 504-517
4. Nielsen OS et al. (1991) Bone metastases: Pathophysiology and management policy. J Clin Oncol 9: 509-524
5. Roodman GD (1996) Advances in bone biology: The osteoclast. Endocr Rev 17: 308-332
6. Simonet WS et al. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319
7. Tsuda E et al. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142
8. Bucay N et al. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268
9. Yasuda H (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OCIF/OPG inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337
10. Yesuda H et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 95: 3597-3602
11. Lacey DL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176
12. Anderson DM et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179
13. Wong BR et al. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 2075-2080
14. Matsuzaki K et al. (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246: 199-204
15. Burgess TL et al. (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527-538
16. O'Brien EA et al. (2000) Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274: 281-290
17. Lacey DL et al. (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435-448
18. Hsu H et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545
19. Body J-J et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (Suppl): S887-S892
20. Whyte MP et al. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347: 175-184
21. Hughes AE et al. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24: 45-48
22. Theoleyre T et al. (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15: 457-475
23. Standal T et al. (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100: 3002-3007
24. Mosheimer BA et al. (2005) Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90: 2964-2971
25. Keller ET and Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718-729
26. Brown JM et al. (2004) OPG, RANKL, and RANK in cancer metastasis: expression and regulation. In The Biology of Skeletal Metastases, 149-172 (Eds Keller ET and Chung LWK) Boston: Kluwer Academic Publishers
27. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80 (Suppl): S1546-S1556
28. Keller ET and Brown JM (2003) Osteoprotegerin, receptor activator of NFκB (RANK) and RANK ligand in cancer. In Research Advances in Cancer 3, 81-93 (Ed Mohan RM) Kerala: Global Research Network
29. Dunstan CR (2005) The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Textbook of Bone Metastases, 51-62 (Eds Jasmin C et al.) Chichester: John Wiley and Sons, Ltd
30. Bhatia P at al. (2005) Expression of receptor activator of NF-kappa B is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162-165
31. Reinholz MM et al. (2002) Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: Analysis by real-time quantitative PCR. Breast Cancer Res Treat 74: 255-269
32. Brown JM et al. (2001) Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57: 611-616
33. Heider U et al. (2003) Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteotytic bone disease in patients with multiple myeloma. Clin Cancer Res 9: 1436-1440
34. Farrugia AN et al. (2003) Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445
35. Ito R et al. (2003) Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 443: 146-151
36. Pearse RN et al. (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 11581-11586
37. Lipton A et al. (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306-2310
38. Seidel C et al. on behalf of The Nordic Myeloma Study Group (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269-2271
39. Kyrtsonis MC et al. (2004) Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72: 252-258
40. Martinetti A et al. (2004) Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 11: 771-779
41. Mizutani Y et al. (2004) Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101: 1794-1802
42. Brown JM et al. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977-2983
43. Eaton CL et al. (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59: 304-310
44. Jung K et al. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111: 783-791
45. Jung K et al. (2003) Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170: 2302-2305
46. Terpos E et al. (2003) Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069
47. Grimaud E et al. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021-2031
48. Sezer O et al. (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098
49. Vanderkerken K et al. (2003) Multiple myeloma biology: Lessons from the 5TMM models. Immunol Rev 194: 196-206
50. Sordillo EM and Pearse RN (2003) RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 97 (Suppl): S802-S812
51. Doran PM et al. (2004) Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 32: 351-359
52. Capparelli C et al. (2000) Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60: 783-787
53. Morony S et al. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61: 4432-4436
54. Zhang J et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244
55. Bakker PJ et al. (2004) A single dose controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in post-menopausal women. J Bone Miner Res 19: 1059-1066
56. Onyia JE et al. (2004) Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 309: 369-379
57. Viereck V et al. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680-686
58. Mackie PS et al. (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951-958
59. Pan B et al. (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-α converting enzyme (TACE). J Bone Miner Res 19: 147-154
60. Corey E et al. (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295-306; Erratum in: Clin Cancer Res 9: 1574-1575
61. Honore P et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521-528
62. Luger NM et al. (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61: 4038-4047
63. Morony S et al. (2005) The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146: 3235-3243
64. Akatsu T et al. (1998) Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23: 495-498
65. Zhang J at al. (2003) Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883-7890
66. Holen I et al. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619-1623
67. Shipman CM and Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor related apoptosis-inducing ligand/ Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916
68. Hausler KD et al. (2004) Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 19: 1873-1881
69. Zhou H et al. (2001) A novel osteoclast-derived C-type lectin that inhibits osteoclast formation. J Biol Chem 276: 14916-14923
70. Hu YS et al. (2004) Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res 19: 89-99
71. Zhou H et al. (2002) Osteoclast inhibitory lectin, a family of new osteoclast inhibitors. J Biol Chem 277: 48808-48815
72. Bendre MS et al. (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37
73. Huang L et al. (2003) Receptor activator of NF-κB ligand (RANKL) is expressed in chondroblastoma: Possible involvement in osteoclastic giant cell recruitment. Mol Pathol 56: 116-120
74. Kumamoto H and Ooya K (2004) Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med 33: 46-52
75. Atkins GJ et al. (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15: 640-649
76. Good CR et al. (2002) Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J Surg Oncol 79: 174-179
77. Sezer O et al. (2002) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99: 4646-4647
78. Giuliani N et al. (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533
79. Huang L et al. (2002) Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 55: 877-878